Clinical Trial Update: Glulisine Pre- and Postmeal [Phase 1]

View source ↗

Summary

Sanofi completed a Phase 1 clinical trial evaluating insulin glulisine administered before and after meals in individuals with Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus Type 1 | Phase 1 | Status: COMPLETED